Evista Coupons & Savings Card – Discount Prices from $34.32

Evista (raloxifene) should not be taken by individuals who are pregnant or may become pregnant, as it can harm the fetus. It is also contraindicated in individuals with a history of blood clots, such as deep vein thrombosis, pulmonary embolism, or retinal vein thrombosis. Additionally, those with a known allergy to raloxifene or any of its components should avoid taking Evista. It is important for individuals to consult with their healthcare provider to determine if Evista is appropriate for their specific medical condition.

The choice between Evista (raloxifene) and Fosamax (alendronate) depends on the specific medical condition being treated and the individual patient's health profile. Evista is typically used for the prevention and treatment of osteoporosis in postmenopausal women and also reduces the risk of invasive breast cancer. Fosamax is used to treat and prevent osteoporosis in postmenopausal women and men, and it can also treat osteoporosis caused by glucocorticoid use and Paget's disease of bone.The decision on which medication is better should be made by a healthcare provider, considering factors such as the patient's medical history, risk factors, potential side effects, and specific health needs. It is important for patients to discuss their options with their healthcare provider to determine the most appropriate treatment for their situation.

Yes, Evista (raloxifene) is known to improve bone density. It is commonly used to treat and prevent osteoporosis in postmenopausal women by mimicking the effects of estrogen on bone tissue, which helps to maintain or increase bone density.

Evista and Prolia are not the same. Evista (raloxifene) is a selective estrogen receptor modulator (SERM) used primarily to treat and prevent osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer. Prolia (denosumab) is a monoclonal antibody used to treat osteoporosis in postmenopausal women at high risk for fracture and to increase bone mass in men with osteoporosis. They work through different mechanisms and are used for similar but distinct purposes.

Raloxifene should generally be avoided in individuals with a history of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, as it may increase the risk of these conditions. It is also contraindicated in those with active or past history of blood clots. Additionally, raloxifene is not recommended for use in premenopausal women, during pregnancy, or in individuals with severe liver impairment. It is important for patients to consult with their healthcare provider to determine if raloxifene is appropriate for their specific medical condition.